Home News Lung cancer incidences due to Osimertinib are higher in real world patients

Lung cancer incidences due to Osimertinib are higher in real world patients

28
0



Study results published in the journal CHEST found that 18% of patients treated with osimertinib were diagnosed with drug-related pneumonitis.
“Drug-related pneumonitis (DRP) associated with first-line osimertinib treatment occurred at a higher rate in the real-world population than in previous study cohorts,” Yuki Sato, MD, of the department of respiratory medicine at Kobe City Medical General Hospital, and colleagues wrote. “[Additionally,] Half the patients presented transient asymptomatic signs.



Continue reading…

Previous articleAccording to superintendents, 13 common misconceptions about the operation of golf courses have been dispelled.
Next articleQ&A: Early-stage investment reinforced well being tech in 2022